Open-label, Single-arm, Multicenter, Long-term Study to Evaluate Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Pediatric Subjects With Epilepsy

Trial Profile

Open-label, Single-arm, Multicenter, Long-term Study to Evaluate Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Pediatric Subjects With Epilepsy

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Brivaracetam (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Registrational
  • Sponsors UCB
  • Most Recent Events

    • 07 Jun 2016 Planned End Date changed from 1 Sep 2017 to 1 Oct 2021.
    • 07 Jun 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Oct 2021.
    • 08 Mar 2013 Planned number of patients changed from 500 to 600 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top